Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024)
Cytosorbents' (CTSO) quarterly Net Equity Issued and Repurchased came in at -$238.0 in Q2 2024, down 100.45% quarter-over-quarter from $53238.0 in Q1 2024.
Powered by 
Analysis
Cytosorbents (CTSO) Net Equity Issued and Repurchased (2012 - 2024) Analysis & Trends
Cytosorbents (CTSO) has reported Net Equity Issued and Repurchased for 4 consecutive years, with -$238.0 the latest figure, recorded in Q2 2024.
- For the quarter ending Q2 2024, Net Equity Issued and Repurchased changed N/A year-over-year to -$238.0; the trailing twelve-month figure through Sep 2024 stood at $694733.0 (changed N/A YoY), and the FY2023 full-year result was $4.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased declined to -$238.0 in Q2 2024 per CTSO's latest filing, from $53238.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $641733.0 in Q1 2023 and bottomed at -$238.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 20.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | - |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | - |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -238.00 |
| Mar 31, 2024 | 53,238.00 |
| Mar 31, 2023 | 641,733.00 |
| Sep 30, 2013 | 700,000.00 |
| Jun 30, 2013 | 450,000.00 |
| Mar 31, 2013 | 450,000.00 |
| Sep 30, 2012 | -2.10 Mn |